#biotechne — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #biotechne, aggregated by home.social.
-
#Merck-Milliardenübernahme: DAX-Konzern kauft #US Riesen #BioTechne
Großübernahme bei Merck: Unter dem neuen Chef Kai Beckmann kauft der DAX-Konzern für fast 10 Milliarden Euro den US-Laborausrüster Bio-Techne. https://www.op-online.de/region/darmstadt/merck-milliardenuebernahme-dax-konzern-kauft-us-riesen-bio-techne-94370869.html?utm_source=_shared&utm_medium=west&utm_campaign=interactionbar -
#Merck-Milliardenübernahme: DAX-Konzern kauft #US Riesen #BioTechne
Großübernahme bei Merck: Unter dem neuen Chef Kai Beckmann kauft der DAX-Konzern für fast 10 Milliarden Euro den US-Laborausrüster Bio-Techne. https://www.op-online.de/region/darmstadt/merck-milliardenuebernahme-dax-konzern-kauft-us-riesen-bio-techne-94370869.html?utm_source=_shared&utm_medium=west&utm_campaign=interactionbar -
#Merck-Milliardenübernahme: DAX-Konzern kauft #US Riesen #BioTechne
Großübernahme bei Merck: Unter dem neuen Chef Kai Beckmann kauft der DAX-Konzern für fast 10 Milliarden Euro den US-Laborausrüster Bio-Techne. https://www.op-online.de/region/darmstadt/merck-milliardenuebernahme-dax-konzern-kauft-us-riesen-bio-techne-94370869.html?utm_source=_shared&utm_medium=west&utm_campaign=interactionbar -
#Merck-Milliardenübernahme: DAX-Konzern kauft #US Riesen #BioTechne
Großübernahme bei Merck: Unter dem neuen Chef Kai Beckmann kauft der DAX-Konzern für fast 10 Milliarden Euro den US-Laborausrüster Bio-Techne. https://www.op-online.de/region/darmstadt/merck-milliardenuebernahme-dax-konzern-kauft-us-riesen-bio-techne-94370869.html?utm_source=_shared&utm_medium=west&utm_campaign=interactionbar -
Merck’s $6.7B Terns buy is less about leukemia than life after Keytruda.
When one drug drives nearly half of revenue, M&A becomes a way to buy time before the patent cliff.
Read:
https://biotech.industryexaminer.com/merck-terns-deal-keytruda-patent-cliff-biotech-m-and-a/#Biotech #Pharma #Merck #Oncology #PatentCliff #BiotechM&A #TechNews #BioTechne
-
Merck’s $6.7B Terns buy is less about leukemia than life after Keytruda.
When one drug drives nearly half of revenue, M&A becomes a way to buy time before the patent cliff.
Read:
https://biotech.industryexaminer.com/merck-terns-deal-keytruda-patent-cliff-biotech-m-and-a/#Biotech #Pharma #Merck #Oncology #PatentCliff #BiotechM&A #TechNews #BioTechne
-
Dayforce ($DAY) reported EPS of $0.47, exceeding the forecast of $0.4294. Revenue was $440M, surpassing the expected $428.34M.
Bio-Techne ($TECH) achieved EPS of $0.42, beating the forecast of $0.38. Revenue reached $289.5M, exceeding the anticipated $280.22M.
Bunge ($BG) posted EPS of $2.29, higher than the forecast of $2.14. However, revenue was $12.91B, falling short of the expected $13.34B.
#Earnings #Q3 #Dayforce #BioTechne #Bunge #Investing #Finance #Stocks #MarketNews
-
Dayforce ($DAY) reported EPS of $0.47, exceeding the forecast of $0.4294. Revenue was $440M, surpassing the expected $428.34M.
Bio-Techne ($TECH) achieved EPS of $0.42, beating the forecast of $0.38. Revenue reached $289.5M, exceeding the anticipated $280.22M.
Bunge ($BG) posted EPS of $2.29, higher than the forecast of $2.14. However, revenue was $12.91B, falling short of the expected $13.34B.
#Earnings #Q3 #Dayforce #BioTechne #Bunge #Investing #Finance #Stocks #MarketNews
-
Dayforce ($DAY) reported EPS of $0.47, exceeding the forecast of $0.4294. Revenue was $440M, surpassing the expected $428.34M.
Bio-Techne ($TECH) achieved EPS of $0.42, beating the forecast of $0.38. Revenue reached $289.5M, exceeding the anticipated $280.22M.
Bunge ($BG) posted EPS of $2.29, higher than the forecast of $2.14. However, revenue was $12.91B, falling short of the expected $13.34B.
#Earnings #Q3 #Dayforce #BioTechne #Bunge #Investing #Finance #Stocks #MarketNews
-
Dayforce ($DAY) reported EPS of $0.47, exceeding the forecast of $0.4294. Revenue was $440M, surpassing the expected $428.34M.
Bio-Techne ($TECH) achieved EPS of $0.42, beating the forecast of $0.38. Revenue reached $289.5M, exceeding the anticipated $280.22M.
Bunge ($BG) posted EPS of $2.29, higher than the forecast of $2.14. However, revenue was $12.91B, falling short of the expected $13.34B.
#Earnings #Q3 #Dayforce #BioTechne #Bunge #Investing #Finance #Stocks #MarketNews